<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recombinant erythropoietin (r-HuEPO) was the first growth factor introduced into clinical practice </plain></SENT>
<SENT sid="1" pm="."><plain>The main indication for its therapeutic use remains treatment of <z:hpo ids='HP_0001903'>anaemias</z:hpo> during <z:hpo ids='HP_0003774'>chronic renal failure</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In Czech Republic it is at present administered to 55% of patients included in a regular haemodialyzation program and in the pre-dialyzation stage of the disease, consistent with European practice </plain></SENT>
<SENT sid="3" pm="."><plain>In addition to a marked improvement of the quality of life, during r-HuEPO treatment also the prevalence of some cardiovascular complications is reduced and immune functions improve </plain></SENT>
<SENT sid="4" pm="."><plain>The list of diseases where r-HuEPO therapy is indicated has been, however, extended nowadays </plain></SENT>
<SENT sid="5" pm="."><plain>A very favourable effect was recorded in some haematological malignicies and <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The best results were observed so far in the treatment of <z:hpo ids='HP_0001903'>anaemia</z:hpo> associated with <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_339'>lymphatic leukaemia</z:mpath>, and also in malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, <z:mp ids='MP_0002038'>carcinoma</z:mp> of the breast and ovary </plain></SENT>
<SENT sid="7" pm="."><plain>It is used also in the treatment of suppressed erythropoiesis resulting from cytoreducing therapy </plain></SENT>
<SENT sid="8" pm="."><plain>Other indications include <z:hpo ids='HP_0001903'>anaemia</z:hpo> after transplantations of bone marrow, preparation before autologous transfusions and some cases of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>The authors mention also other contemporary possibilities of r-HuEPO use </plain></SENT>
</text></document>